BC Week In Review | Jul 18, 2011
Company News

NuRx, QuantRx diagnostic news

The companies settled a suit in the Delaware Court of Chancery concerning control of their JV, QN Diagnostics LLC. The JV was formed last July to develop and commercialize point-of-care diagnostics. NuRx, which will become...
BC Week In Review | Sep 13, 2010
Company News

QuantRx management update

QuantRx Biomedical Corp. (OTCBB:QTXB) Doylestown, Pa.   Business: Diagnostic   Departing: Sasha Afanassiev as CFO   Hired: Barry London as interim CEO and a director; he replaces Walter Witoshkin, who stepped down as chairman and...
BC Week In Review | Sep 13, 2010
Company News

QuantRx board of directors update

QuantRx Biomedical Corp. (OTCBB:QTXB) Doylestown, Pa.   Business: Diagnostic   Appointed: Shalom Hirschman, a director, as chairman; he replaces Walter Witoshkin, who stepped down as chairman and CEO  ...
BC Week In Review | Jun 14, 2010
Clinical News

Q-Reader thyroid testing system regulatory update

QuantRx submitted a 510(k) application to FDA for its Q-Reader thyroid testing system as a point-of-care in vitro diagnostic for thyroid testing. QuantRx Biomedical Corp. (OTCBB:QTXB), Doylestown, Pa.   Product: Q-Reader thyroid testing system  ...
BC Week In Review | Feb 8, 2010
Company News

NuRx, QuantRx deal

QuantRx will acquire partner NuRx in a stock deal valued at $15.2 million based on QuantRx's close of $0.42, on Jan. 28, the day before the deal was announced. NuRx shareholders will receive 1.5 QuantRx...
BC Week In Review | Aug 10, 2009
Company News

NuRx, QuantRx deal

The companies formed QN Diagnostics LLC, a 50/50 JV that will develop and commercialize point-of-care diagnostics using QuantRx' RapidSense diagnostics technology, including a line of CLIA-waived quantitative lateral flow diagnostics for undisclosed indications. NuRx will...
BC Week In Review | Jan 19, 2009
Clinical News

RapidSense Phencyclidine regulatory update

FDA granted 510(k) clearance for QuantRx's RapidSense Phencyclidine (PCP) Test as a point-of-care diagnostic for PCP testing. A RapidSense test for methamphetamine was approved earlier this month. QuantRx Biomedical Corp. (OTCBB:QTXB), Doylestown, Pa.   Product:...
BC Week In Review | Jan 12, 2009
Clinical News

RapidSense Methamphetamine Test regulatory update

FDA granted 510(k) clearance for QuantRx's RapidSense Methamphetamine Test as a point-of-care diagnostic for methamphetamine testing. QuantRx Biomedical Corp. (OTCBB:QTXB), Doylestown, Pa.   Product: RapidSense Methamphetamine Test   Business: Diagnostic  ...
BC Week In Review | Jan 20, 2003
Company News

Maxim Pharmaceuticals board of directors update

Maxim Pharmaceuticals Inc. (SSE:MAXM; MMP), San Diego, Calif.   Business: Cancer, Infectious diseases   Appointed: Robert Zerbe, CEO of QuantRx Pharmaceuticals Co.  ...
Items per page:
1 - 9 of 9
BC Week In Review | Jul 18, 2011
Company News

NuRx, QuantRx diagnostic news

The companies settled a suit in the Delaware Court of Chancery concerning control of their JV, QN Diagnostics LLC. The JV was formed last July to develop and commercialize point-of-care diagnostics. NuRx, which will become...
BC Week In Review | Sep 13, 2010
Company News

QuantRx management update

QuantRx Biomedical Corp. (OTCBB:QTXB) Doylestown, Pa.   Business: Diagnostic   Departing: Sasha Afanassiev as CFO   Hired: Barry London as interim CEO and a director; he replaces Walter Witoshkin, who stepped down as chairman and...
BC Week In Review | Sep 13, 2010
Company News

QuantRx board of directors update

QuantRx Biomedical Corp. (OTCBB:QTXB) Doylestown, Pa.   Business: Diagnostic   Appointed: Shalom Hirschman, a director, as chairman; he replaces Walter Witoshkin, who stepped down as chairman and CEO  ...
BC Week In Review | Jun 14, 2010
Clinical News

Q-Reader thyroid testing system regulatory update

QuantRx submitted a 510(k) application to FDA for its Q-Reader thyroid testing system as a point-of-care in vitro diagnostic for thyroid testing. QuantRx Biomedical Corp. (OTCBB:QTXB), Doylestown, Pa.   Product: Q-Reader thyroid testing system  ...
BC Week In Review | Feb 8, 2010
Company News

NuRx, QuantRx deal

QuantRx will acquire partner NuRx in a stock deal valued at $15.2 million based on QuantRx's close of $0.42, on Jan. 28, the day before the deal was announced. NuRx shareholders will receive 1.5 QuantRx...
BC Week In Review | Aug 10, 2009
Company News

NuRx, QuantRx deal

The companies formed QN Diagnostics LLC, a 50/50 JV that will develop and commercialize point-of-care diagnostics using QuantRx' RapidSense diagnostics technology, including a line of CLIA-waived quantitative lateral flow diagnostics for undisclosed indications. NuRx will...
BC Week In Review | Jan 19, 2009
Clinical News

RapidSense Phencyclidine regulatory update

FDA granted 510(k) clearance for QuantRx's RapidSense Phencyclidine (PCP) Test as a point-of-care diagnostic for PCP testing. A RapidSense test for methamphetamine was approved earlier this month. QuantRx Biomedical Corp. (OTCBB:QTXB), Doylestown, Pa.   Product:...
BC Week In Review | Jan 12, 2009
Clinical News

RapidSense Methamphetamine Test regulatory update

FDA granted 510(k) clearance for QuantRx's RapidSense Methamphetamine Test as a point-of-care diagnostic for methamphetamine testing. QuantRx Biomedical Corp. (OTCBB:QTXB), Doylestown, Pa.   Product: RapidSense Methamphetamine Test   Business: Diagnostic  ...
BC Week In Review | Jan 20, 2003
Company News

Maxim Pharmaceuticals board of directors update

Maxim Pharmaceuticals Inc. (SSE:MAXM; MMP), San Diego, Calif.   Business: Cancer, Infectious diseases   Appointed: Robert Zerbe, CEO of QuantRx Pharmaceuticals Co.  ...
Items per page:
1 - 9 of 9